Gilead Sciences (GILD) Expected to Announce Earnings on Thursday

Gilead Sciences (NASDAQ:GILD - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Thursday, April 24th. Analysts expect Gilead Sciences to post earnings of $1.73 per share and revenue of $6.77 billion for the quarter. Gilead Sciences has set its FY 2025 guidance at 7.700-8.100 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts expect Gilead Sciences to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Price Performance

GILD stock traded down $0.23 during midday trading on Thursday, reaching $106.15. The company had a trading volume of 10,105,445 shares, compared to its average volume of 7,533,802. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a 50 day moving average price of $109.21 and a 200-day moving average price of $97.88. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market capitalization of $132.17 billion, a price-to-earnings ratio of 286.89, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is 854.05%.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Cantor Fitzgerald began coverage on Gilead Sciences in a research note on Tuesday. They set an "overweight" rating and a $125.00 target price for the company. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Ten analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $106.92.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the sale, the chief financial officer now owns 171,223 shares in the company, valued at $17,502,415.06. This represents a 44.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 302,785 shares of company stock worth $30,540,875. Company insiders own 0.27% of the company's stock.

Hedge Funds Weigh In On Gilead Sciences

An institutional investor recently raised its position in Gilead Sciences stock. Brighton Jones LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,359 shares of the biopharmaceutical company's stock after purchasing an additional 2,450 shares during the period. Brighton Jones LLC's holdings in Gilead Sciences were worth $1,326,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.